Joana Correia, Co-Founder and CEO, Exogenus Therapeutics, commented, “This collaboration with Lonza will be essential to ...
Hosted on MSN1mon
Berenberg raises Lonza stock price target to CHF680This adjustment followed Lonza's 2024 sales report of CHF6.6 billion and a core EBITDA margin of 29.0%, despite a contract termination with Moderna (NASDAQ:MRNA). Underlying sales grew by 7% due ...
Exogenus Therapeutics Taps Lonza to Develop a GMP-Compliant Process for Lead Exosome-Based Candidate
Lonza will leverage its expertise in exosome development and analytical services to define a GMP-compliant process for Exo-101 production.
PORTSMOUTH — The Pease Development Authority’s Board of Directors voted to approve the concept plan for Lonza Biologics Inc., ...
Dr. Slaoui has sat on several biotechnology company boards, including Moderna, Inc. and Lonza Group AG, and he chaired the boards of Galvani, and Vaxcyte, a vaccine development platform company.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback